{"id":59413,"date":"2026-03-13T21:48:40","date_gmt":"2026-03-13T13:48:40","guid":{"rendered":"https:\/\/flcube.com\/?p=59413"},"modified":"2026-03-13T21:48:41","modified_gmt":"2026-03-13T13:48:41","slug":"cms-launches-opzelura-nationwide-first-topical-jak-inhibitor-for-vitiligo-reaches-1300-pharmacies-across-30-chinese-provinces","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59413","title":{"rendered":"CMS Launches Opzelura Nationwide \u2013 First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces"},"content":{"rendered":"\n

China Medical System Holdings (CMS; HKG: 0867<\/a>)<\/strong> announced that first prescriptions<\/strong> of Ruxolitinib Phosphate Cream (Opzelura)<\/strong> have been issued to vitiligo patients across 30 provincial-level administrative regions<\/strong> in China. The product achieved synchronized availability at over 1,300 offline pharmacies<\/strong> and the JD.com e-commerce platform<\/strong>, marking the commercial debut of China’s first approved topical JAK inhibitor<\/strong> for vitiligo treatment.<\/p>\n\n\n\n

Launch Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Product<\/strong><\/td>Ruxolitinib Phosphate Cream (Opzelura)<\/td><\/tr>
Developer<\/strong><\/td>Incyte Corporation (originator); CMS (China\/Southeast Asia rights)<\/td><\/tr>
Indication<\/strong><\/td>Vitiligo (first topical JAK inhibitor approved in China)<\/td><\/tr>
NMPA Approval<\/strong><\/td>January 2026<\/td><\/tr>
Commercial Launch<\/strong><\/td>12\u202fMar\u202f2026 (first prescriptions)<\/td><\/tr>
Geographic Reach<\/strong><\/td>30 provincial-level regions<\/td><\/tr>
Distribution<\/strong><\/td>1,300+ offline pharmacies + JD.com e-commerce<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Licensing & Rights Structure<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Deal Date<\/strong><\/td>2\u202fDec\u202f2022<\/td><\/tr>
Licensor<\/strong><\/td>Incyte Corporation<\/td><\/tr>
Licensee<\/strong><\/td>China Medical System Holdings (CMS)<\/td><\/tr>
Exclusive Rights<\/strong><\/td>Development, registration, commercialization in Mainland China, Hong Kong, Macau, Taiwan, and 11 Southeast Asian countries<\/strong><\/td><\/tr>
Manufacturing Rights<\/strong><\/td>Non-exclusive<\/td><\/tr>
Mechanism<\/strong><\/td>Selective JAK1\/JAK2 inhibitor<\/strong> (topical formulation)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Commercial Strategy<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
Vitiligo Prevalence<\/strong><\/td>~12 million patients<\/strong> in China; significant unmet need with limited approved therapies<\/td><\/tr>
JAK Inhibitor Class<\/strong><\/td>Oral JAK inhibitors (tofacitinib, ruxolitinib tablets) used off-label; Opzelura offers first topical option with favorable safety profile<\/td><\/tr>
Distribution Innovation<\/strong><\/td>Simultaneous offline + JD.com launch enables rapid patient access; e-commerce channel targets younger demographic and stigma-conscious patients<\/td><\/tr>
Revenue Potential<\/strong><\/td>Peak sales estimated RMB 500\u2013800 million annually<\/strong> in China; Southeast Asia expansion adds incremental $50\u2013100 million<\/strong> opportunity<\/td><\/tr>
Competitive Moat<\/strong><\/td>3\u20135 year first-mover advantage vs. pending topical JAK inhibitors (Pfizer, AbbVie in development)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n